Trial Profile
A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Large cell carcinoma
- Focus Therapeutic Use
- 15 Sep 2013 New trial record